Germ-line MTHFR C677T, FV H1299R and PAI-1 5G/4G variations in breast carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2903-2908

  Ozen, Filiz ^a   Erdis, Eda ^a   Sik, Ebru ^b   Silan, Fatma ^b   Uludag, Ahmet ^b   Ozdemir, Ozturk ^a,b  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

A1298C; Breast carcinoma; FV Leiden; MTHFR C677T; PAI 1 5G 4G; R2; SNPs

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ADENOCARCINOMA; BREAST TUMOR; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; TURKEY;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHATIC METASTASIS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; TURKEY;

EID: 84880362023     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2903     Document Type: Article

References (45)

1. Akbari M, Donenberg T, Lunn J, et al (2013). The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet. [Epub ahead of print].
2. Akram M, Malik FA, Kayani MA (2012).Mutational analysis of the MTHFR gene in breast cancer patients of Pakistani population. Asian Pac J Cancer Prev. 13, 1599-603.
3. Bhar A, Haubrock M, Mukhopadhyay A, et al (2013). Coexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cell. Algorithms Mol Biol, 8, 9.
4. Bonache S, de la Hoya M, Gutierrez-Enriquez S, et al (2013). Mutation analysis of the SHFM1 gene in breast/ovarian cancer families. J Cancer Res Clin Oncol, 139, 529-32.
5. Carraro DM, Koike Folgueira MA, Garcia Lisboa BC, et al (2013). Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: A Portrait of Early-Onset Breast Cancer in Brazil. PLoS One, 8, 57581.
6. Chang S, Sharan SK (2012).The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression. Transcription, [Epub ahead of print].
7. de Càssia Carvalho Barbosa R, da Costa DM, Cordeiro DE, et al (2012). Interaction of MTHFR C677T and A1298C, and MTR A2756G gene polymorphisms in breast cancer risk in a population in Northeast Brazil. Anticancer Res, 32, 4805-811.
8. Descotes F, Riche B, Saez S, et al (2008).Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer., 8, 168-77.
9. Diakite B, Tazzite A, Hamzi K, et al (2012). Methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Moroccan women. Afr Health Sci, 12, 204-9.
10. Eljuga D, Razumovic JJ, Bulic K, et al (2011). Prognostic importance of PAI-1 in node negative breast cancer patients- -results after 10 years of follow up. Pathol Res Pract. 207, 290-4.
11. Ericson U, Sonestedt E, Ivarsson MI, et al (2009). Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the malmö diet and cancer cohort. Cancer Epidemiol Biomarkers Prev 18,1101-10.
12. Eroglu A, Akar N (2010). Methylenetetrahydrofolate reductase C677T polymorphism in breast cancer risk. Breast Cancer Res Treat 122, 897-8.
13. Eroglu A, Akar N (2011). Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifenassociated thromboembolism in breast cancer patients. Thromb Res 127, 384-5.
14. Fersching DM, Nagel D, Siegele B, et al (2012).Apoptosisrelated biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res 32, 2047-58.
15. Gao CM, Tang JH, Cao HX, et al (2009). MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. J Hum Genet 54, 414-8.
16. Henríquez-Hernàndez LA, Murias-Rosales A, Gonzàlez- Hernàndez A, et al (2010). Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol 34, 634-38.
17. Hildenbrand R, Schaaf A, Dorn-Beineke A, et al (2009). Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 24, 869-77.
18. Hosseini M, Houshmand M, Ebrahimi A (2011). MTHFR polymorphisms and breast cancer risk. Arch Med Sci 7, 134-7.
19. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, et al (2011). Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. Tumori 97, 532-59.
20. Jeong YJ, Jeong HY, Bong JG, et al (2013). Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer. Oncol Rep, [Epub ahead of print].
21. Jiao Z, Li D (2013). Lack of association between MHTFR Glu429Ala polymorphism and breast cancer susceptibility: a systematic review and meta-analysis of 29 research studies. Tumour Biol, [Epub ahead of print].
22. Lee JH, Kim Y, Choi JW, Kim YS (2013). Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch Med Res 44, 39-45.
23. Li H, Beeghly-Fadiel A, Wen W, et al (2013). Gene-environment interactions for breast cancer risk among Chinese women: a report from the Shanghai breast cancer genetics study. Am J Epidemiol 177, 161-70.
24. Martin FL (2013). Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility. ISRN Oncol 2013, 624794.
25. Martinelli N, Girelli D, Ferraresi P, et al (2007). Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism. Blood Coagul Fibrinolysis 18, 125-9.
26. Meryet-Figuières M, Resina S, Lavigne C, et al (2007). Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range. Biochimie 89, 1228-33.
27. Muzeyyen I (2013). A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk. Mol Biol Rep 40, 625-37.
28. Nomizu T, Matsuzaki M, Katagata N, et al (2012). A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes. Breast Cancer, [Epub ahead of print].
29. Offersen BV, Alsner J, Ege OK, et al (2008).A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol, 47, 618-32. Ozdemir O, Yenicesu GI, Silan F, et al (2012). Recurrent pregnancy loss and its relation to combined parental thrombophilic gene mutations. Genet Test Mol Biomarkers 16, 279-86.
30. Ozdemir O, Yenicesu GI, Silan F, et al (2012). Recurrent pregnancy loss and its relation to combined parental thrombophilic gene mutations. Genet Test Mol Biomarkers 16, 279-86.
31. Oztürk A, Balli S, Akar N (2012). Determination of factor V Leiden mutation and R2 polymorphism in cis position. Clin Appl Thromb Hemost, [Epub ahead of print].
32. Qi X, Ma X, Yang X, et al (2010). Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a metaanalysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat 123, 499-06.
33. Sangrajrang S, Sato Y, Sakamoto H, et al (2010). Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women. Breast Cancer Res Treat 123, 885-93.
34. Sohail A, Kanwal N, Ali M, et al (2013). Effects of glutathione- S-transferase polymorphisms on the risk of breast cancer: A population-based case-control study in Pakistan. Environ Toxicol Pharmacol 35, 143-53.
35. Tang L, Han X (2013). The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67, 179-82.
36. Valjevac A, Mehic B, Kiseljakovic E, et al (2013). Prevalence of 1691G>A FV mutation in females from Bosnia and Herzegovina - a preliminary report. Bosn J Basic Med Sci 13, 31-3.
37. Valjevac A, Mehic B, Kiseljakovic E, et al (2013). Prevalence of 1691G>A FV mutation in females from Bosnia and Herzegovina - a preliminary report. Bosn J Basic Med Sci 13, 31-3.
38. Vrba L, Muñoz-Rodríguez JL, Stampfer MR, et al (2013). miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One, 8, 54398. Werner H, Bruchim I (2013). IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 13, 537-44.
39. Werner H, Bruchim I (2013). IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 13, 537-44.
40. Wu XY, Ni J, Xu WJ, et al (2012). Interactions between MTHFR C677T-A1298C variants and folic acid deficiency affect breast cancer risk in a Chinese population. Asian Pac J Cancer Prev 13, 2199-06.
41. Xu X, Gammon MD, Hernandez-Vargas H, et al (2012). DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J 26, 2657-66.
42. Yagmurdur MC, Atac FB, Tutar NU, et al (2008). Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast. Int Surg 93, 163-8.
43. Yamazaki T, Nicolaes GA, Sørensen KW, Dahlbäck B (2002). Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. Blood 100, 2515-21.
44. Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RA (2006). Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathology 38, 442-4.
45. Zheng J, Wang J, Sun X, et al (2013). HIC1 modulates prostate cancer progression by epigenetic modification. Clin Cancer Res, [Epub ahead of print].